Organization · Venture Capital
Quan Capital 泉创资本
Quan Capital is a Shanghai-based venture capital firm specializing in early and growth-stage investments in life sciences, particularly in therapeutics and enabling technologies. The firm leverages its global network and local expertise to support innovative healthcare solutions.
Overview
What Quan Capital 泉创资本 does
What Quan Capital 泉创资本 is
Quan Capital is a Shanghai-based venture capital firm specializing in early and growth-stage investments in life sciences, particularly in therapeutics and enabling technologies. The firm leverages its global network and local expertise to support innovative healthcare solutions.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2018
- Approximate age
- About 8 years
- Structured capabilities
- Funder
- Last reviewed
- April 26, 2026
Official channels
Find Quan Capital 泉创资本 elsewhere
Open the official website or a supported primary organization account.
Capability profile
Quan Capital 泉创资本 as a funder
Investment thesis
Quan Capital aims to discover, incubate, and grow next-generation life sciences companies that address critical healthcare challenges, particularly in China. They focus on breakthrough therapies and cutting-edge technologies within the evolving healthcare landscape.
Focus narrative
Quan Capital invests in early and growth-stage life sciences companies globally, with a particular focus on China. Their investment strategy encompasses therapeutic biotech and pharma, enabling technologies, high-end specialty services, companion diagnostics, and precision medicine. The firm is particularly interested in companies that are developing innovative solutions in oncology, immunology, and rare diseases.
Value beyond capital
Quan Capital adds value to its portfolio companies through hands-on support in strategy, operations, and development. The firm leverages its extensive networks in the biotech industry to facilitate cross-border collaboration and commercialization, particularly in navigating the complexities of the Chinese healthcare market.
Focus and fit
- Stages
- Pre-seed · Seed · Series A · Series B · Series C · Growth Equity
- Regions
- Global · Asia
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 11
- Recorded notable exits
- ARMO Biosciences and dMed
Portfolio context
Notable portfolio companies include: Adcentrx: Developing protein-conjugate therapeutics for cancer. Adicet: Focused on allogeneic gamma delta T cell therapies. Alebund: Late clinical-stage biopharma for renal disease therapies. ARCELLX: Developing CAR-T cell therapies. Centrexion: Non-opioid therapies for chronic pain management. Crescendo Biologics: Developing Humabody therapeutics. Design Therapeutics: Therapies based on the GeneTAC™ platform. iCarbonX: Life sciences technology platform. NextCure: Immunotherapy-based biologics for cancer. Oricell: Specializing in cell therapy for solid tumors. Tempest: Focusing on immune-related pathways in oncology.
Common questions
What to know about Quan Capital 泉创资本
Upseed classifies Quan Capital 泉创资本 under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
April 26, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.